Recently listed Arecor Therapeutics PLC (LON:AREC) said it is making progress in line with expectations outlined at the time of its flotation in early June.
During the first half of 2021, Arecor added to its partner portfolio of global pharmaceutical companies with three new agreements with Hikma, Eli Lilly and Par Sterile Products. Arecor will apply its Arestat technology, which enhances the properties of therapeutic proteins, peptides and vaccines, to deliver superior reformulations of its partners proprietary products, it told investors.
In June, Arecor presented data at the Advanced Technologies and Treatments for Diabetes (ATTD) conference following the successful results of its Phase 1 study of AT247 ultra-rapid acting insulin, in which AT247 demonstrated faster insulin absorption with an accelerated Pharmacokinetic (PK) and Pharmacodynamic (PD) profile compared to NovoRapid and Fiasp.
Preparation is also underway for the commencement of a three day insulin pump clinical trial with AT247. The Phase I clinical trial for AT278, an ultra-concentrated rapid acting insulin, continues to progress, with top-line results expected later this year.
"A key focus for H2 [second half of] 2021 is the Phase I clinical trial for AT278 which, if successful, would add significantly to the diabetes franchise and build on the positive data from the phase 1 study of AT247,” said Sarah Howell, the chief executive officer of Arecor.
“We continue to build momentum across the business with strong progress across our in-house proprietary pipeline and further strengthening of our partner portfolio with new agreements with Hikma, Lilly and Par, further demonstrating the strength of our Arestat platform. With a robust financial base now in place following our successful IPO on AIM in June, we look forward to improving patient care by bringing innovative medicines to market and in doing so building further shareholder value,” she added.